Superworth

Amylyx Pharmaceuticals revenue AMLX

Sales by quarter and over the last twelve months, from 2021.

Last 12 months, to Sep 30, 2025
n/m
a quarter missing
Latest quarter, Q3 FY25
$0
−100% on a year earlier
Fiscal year 2023
$380.8M

Amylyx Pharmaceuticals' twelve-month revenue can't be added up yet: a quarter of its results is missing from our data.

In its latest quarter, Q3 FY25, it was $0, down 100% on the same quarter a year before.

Revenue over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearRevenueChange
FY2023$380.8Mn/a
FY2022n/an/a
FY2021n/an/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedRevenueOn a year earlierLast 12 months
Q3 FY25$0−100%n/a
Q2 FY25$0n/an/a
Q1 FY25$0−100%n/a
Q3 FY24$416K−100%$196.5M
Q2 FY24−$1M−101%$298.8M
Q1 FY24$88.6M+24%$398M
Q4 FY23$108.4M+396%$380.8M
Q3 FY23$102.7M+29666%$294.2M
Q2 FY23$98.2Mn/a$191.9M
Q1 FY23$71.4Mn/an/a
Q4 FY22$21.9Mn/an/a
Q3 FY22$345K+21%n/a

Against its peers

Companies in Drug Manufacturers - General nearest Amylyx Pharmaceuticals' size, closest first, today.

CompanyRevenue, 12 monthsGrowth
AMLXAmylyx Pharmaceuticalsn/m
NRIXNurix Therapeutics$701.9M
OGNOrganon$6.1B−2% a year
LQDALiquidia$450.9M
ARQTArcutis Biotherapeutics$464M+76% a year
PBHPrestige Consumer Healthcare$1.1B−1% a year
INDVIndivior Pharmaceuticals$1.3B+13% a year
HRMYHarmony Biosciences$959.9M+24% a year
ANIPANI Pharmaceuticals$978.4M+31% a year
PAHCPhibro Animal Health$1.5B+17% a year
KNSAKiniksa Pharmaceuticals International$840.8M+59% a year
Peer median$969.1M

What the revenue tells you

Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.

Growing revenue with shrinking margins is a warning, not a win.

More on Amylyx Pharmaceuticals

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.